Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Next Previous
X
Search
Trial Profile

A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lomustine (Primary) ; Onfekafusp alfa (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GLIOSTAR
  • Sponsors Philogen

    • Most Recent Events

    • 05 Apr 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Mar 2025.
    • 07 Nov 2023 According to a Philogen media release, regulatory activities aimed to open 18-20 clinical centers in Germany, Italy, Switzerland, and France are ongoing.
    • 25 May 2023 According to a Philogen media release, Phase II randomized part is bout to start.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top